In contrast, when the tumor cells were injected into immunocompetent wild-type hosts, all sarcomas from wild-type mice grew progressively, while 8 of 20 (40%) sarcomas from RAG2-deficient mice were rejected (18). The gene discussed is RAG2; the disease is sarcoma.